Systemic Delivery and Biodistribution of Cisplatin in Vivo

Authors

Yu-Hsuan Chu, Portland State University
Martha Sibrian-Vazquez, Portland State UniversityFollow
Jorge O. Escobedo, Portland State UniversityFollow
Amanda R. Phillips, Oregon Health & Science University
D. Thomas Dickey, Oregon Health & Science University
Qi Wang, Oregon Health & Science UniversityFollow
Martina Ralle, Oregon Health & Science University
Peter S. Steyger, Oregon Health & Science UniversityFollow
Robert M. Strongin, Portland State UniversityFollow

Sponsor

This work was supported by the National Institute on Deafness and Other Communication Disorders (R21 DC010231; R01 DC012588) and the National Center for Research Resources (RR025512) at the National Institutes of Health for elemental analysis and by the National Science Foundation (Grant 0741993) for the purchase of the LTQ-Orbitrap Discovery.

Published In

Molecular Pharmaceutics

Document Type

Citation

Publication Date

8-1-2016

Abstract

Cisplatin is widely used to treat a variety of cancers. However, ototoxicity and nephrotoxicity remain serious side effects of cisplatin-based chemotherapy. In order to inform the study of cisplatin’s off-target effects, a new drug–fluorophore conjugate was synthesized that exhibited utility as a tracer to determine the cellular uptake and in vivo distribution of cisplatin. This probe will serve as a useful tool to facilitate investigations into the kinetics and biodistribution of cisplatin and its associated side effects in preclinical models after systemic administration.

Locate the Document

https://doi.org/10.1021/acs.molpharmaceut.6b00240

DOI

10.1021/acs.molpharmaceut.6b00240

Persistent Identifier

http://archives.pdx.edu/ds/psu/18858

Citation Details

Chu, Y., Sibrian-Vazquez, M., Escobedo, J. O., Phillips, A. R., Dickey, D. T., Wang, Q., & ... Strongin, R. M. (2016). Systemic Delivery and Biodistribution of Cisplatin in Vivo. Molecular Pharmaceutics, 13(8), 2677-2682.